Effect of high-fat-fructose diet on synaptic plasticity in hippocampus and lipid profile of blood serum of rat: pharmacological possibilities of affecting risk factors

Michalikova, Dominika; Kaprinay, Barbara; Lipták, Boris; Švík, Karol; Slovák, Lukáš; Sotníková, R; Bezek, S; Gaspárová, Zdenka

doi:10.2478/afpuc-2018-0008

Cited by 2 publications

(1 citation statement)

References 19 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood samples were taken from all the animals. After 5 weeks of the diet, all the animals developed metabolic syndrome assessed by means of elevated total cholesterol, LDL cholesterol, triacylglycerol level, glucose and atrial pressure (not published), and decreased HDL cholesterol (27).…”

Section: Animals and Animal Modelmentioning

confidence: 99%

Anti-arrhythmic and cardio-protective effects of atorvastatin and a potent pyridoindole derivative on isolated hearts from rats with metabolic syndrome

Lipták¹,

Knézl²,

Gaspárová³

2019

BLL

View full text Add to dashboard Cite

OBJECTIVES: Aims of this study were to investigate the anti-arrhythmic and cardio-protective effect of atorvastatin and of a new pyridoindole derivative (SMe1EC2) on isolated and perfused hearts while following the Langendorff principles. BACKGROUND: Metabolic syndrome is a widely distributed condition progressing to cardiovascular disease. Many of the metabolic syndrome patients take (HMG)-co-enzyme A (CoA) reductase inhibitors with potential cardioprotective effects. SMe1EC2 is a promising new drug, exerting many positive effects in experimental settings. METHODS: Rats with induced metabolic syndrome were treated with atorvastatin (25 mg/kg) and SMe1EC2 (25 mg/kg and 0.5 mg/kg, respectively) daily for 3 weeks. After the treatment, the hearts were isolated and perfused according to Langendorff. RESULTS: Both atorvastatin and SMe1EC2 improved cardiac function by elevating the left ventricular developed pressure (VLDP) and cardiac contractility. Both SMe1EC2-treated groups improved LVDP during reperfusion, signifi cantly increased-dP/dt, and moderately elevated +dP/dt values. The treatment with both atorvastatin and SMe1EC2 (25 mg/kg) signifi cantly reduced malignant arrhythmia in comparison to control group and group treated with SMe1EC2 0.5 mg/kg. CONCLUSIONS: Owing to its anti-arrhythmic and cardio-protective effects, atorvastatin and SMe1EC2 could be of benefi t to patients suffering from metabolic syndrome (Tab.

show abstract

Section: Animals and Animal Modelmentioning

confidence: 99%